I've been a critical poster (I don't consider myself negative) so here are some positive perspectives.

1. The extension of the debenture eliminates a critical stress point.
2. The fact that Hepalink didn't try to take the "crown jewels" (IP) suggests to me that my hypothesis that they are preditory was wrong.
3. It also suggests that Hepa are collaborative partners. Hence they should be doing Covid trials in China.
4. The extension buys time. Don should actively be sourcing the $20MM needed for BoM2  and not betting on Covid revenue which may take years to generate. Get on with the BoM2 trial now!
5. In this window of opportunity Don and the BOD should aggressively be in the hunt for a biotech finance CEO. Nothing is getting done. It's time to put a "doer" in the CEO slot.

On a separate point I noticed when I listened to the Biotech Investors presentation again that apabetalone was discovered in 2006. The story of apabetalone has had many sweet victories on it's journey, such as when it was discovered that apabetalone works in an epigenetic fashion, the trial when they proved apabetalone increases apolipoprotein-1 (the most important molecule in HDL), all of the post hoc discoveries in DM & CKD, the PAH results recently released. The positive stories to tell are almost remarkable but there are great story tellers and less effective story tellers. Eversana should take the bull by the horns and insure the apabetalone story is presented to the public in the most professional and energetic manner. They should groom presenters from their roster to become the public face of RVX...professional, dynamic, intelligent, youthful, scientific, etc. They could skript 1 major story per month or more frequently about this little Canadian success story and showcase Don and Dr Wong when appropriate. It is too big of an opportunity to miss.

Anyway, glad the debenture stress is deferred for a year.

GLTA. Hopefully we'll be shown some respect so and receive a Covid update.

Toinv